Podcast and Report: Insights and Recommendations for Organizational DEI Strategies
April 2, 2022
Ensuring diversity, equity, and inclusion in rare disease organizations requires focus programs that engage all stakeholders. According to a nine-month project just completed by RARE-X, the project was undertaken to provide a general overview of the rare disease landscape regarding DEI issues and offer recommendations to support RARE-X’s efforts to ensure the long-term development of an inclusive rare disease data platform.
Daniel Levine spoke to:
- Teneasha Washington, Diversity, Equity and Inclusion Lead for RARE-X,
- J.P. Sacksteder, Senior Director of Patient Advocacy Relations for Genentech, and
- Nancy O’Donnell, Director of Outreach for the Usher Syndrome Coalition.
The three discuss the RARE-X report, their own experiences around DEI issues, and how to best address the challenges they’ve encountered.
Related
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
When Stealth Biotherapeutics sought approval for its experimental therapy to treat the ultra-rare and life-threatening condition Barth […]
Read morePowering Cells in People with Rare Mitochondrial Myopathies
Read morePowering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapies
Read moreDeveloping a New Class of Therapies Based on a Natural Cargo Carrier
Read moreReaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
Read moreOne Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Read moreTreating Rare Endocrine Disorders with Therapeutic Peptides
Read moreAn Open Science Data Challenge to Address Rare Neurodevelopment Diseases
RARE-X will kick off Xcelerate RARE: A Rare Disease Open Science Data Challenge this spring. For this […]
Read more